NRIX at a glance
Nurix Therapeutics, Inc. (NRIX, SEC CIK 1549595) filed its latest 10-K annual report on January 28, 2026, a 10-Q quarterly report on October 13, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended November 30, 2025 (FY2025), Nurix Therapeutics, Inc. (NRIX) reported revenue of $84.0 million (up 54.0% from FY2024) and a net loss of $264.5 million. Diluted EPS was -$3.05.
- As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Nurix Therapeutics, Inc. (NRIX) shares worth $913.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by van Houte Hans on November 4, 2026 of 3,300 shares at $15.38 per share.
- In the last 90 days, NRIX insiders reported 0 open-market purchases ($0) and 15 open-market sales ($1.7M) on Form 4, a net sale of $1.7M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $84.0M
- +54.0% vs prior year
- Insiders · 90 days
- 0 buys · 15 sells
- Net −$1.7M
- 13F holders
- 29 funds
- $913.8M · +1 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Nov 30, 2025
Business Overview
- Clinical stage biopharma focused on targeted protein degradation using AI-integrated DEL-AI platform for oncology, inflammation, and immunology treatments
- Advanced lead BTK degrader bexobrutideg in Phase 2 pivotal trial with FDA Fast Track and EMA PRIME designations for relapsed/refractory CLL and WM
- Resumed Phase 1 study of dual BTK/Ikaros/Aiolos degrader zelebrudomide after FDA partial clinical hold lifted in 2024
- $482M non-dilutive funding through collaborations with Gilead, Sanofi, Pfizer; potential $6.1B future milestones and royalties
- Introduced oral CBL-B inhibitor NX-1607 in Phase 1 trials for solid tumors and gained UK Innovation Passport in 2022 for accelerated market access
Risk Factors
- Regulatory risk: FDA partial clinical hold on zelebrudomide enrollment in 2023 due to manufacturing change, lifted in August 2024
- Macroeconomic risk: Uncertainty from inflation, interest rates, tariffs, debt ceiling risks, and global conflict impacts clinical trials, supply chain, personnel
- Operational risk: Dependency on third-party manufacturing for chirally controlled zelebrudomide form critical to ongoing Phase 1b dose escalation
- Market disruption risk: Competitive threat from established BTK inhibitors and non-covalent BTK inhibitors used in relapsed/refractory CLL patients
- Financial risk: Net losses of $264.5 million in FY 2025 with $592.9 million cash runway for only 12 months, needing substantial additional capital beyond that
Management Discussion & Analysis
- Forward-looking statements mention risks and uncertainties without specific guidance or outlook
AI summary of the NRIX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Aug 31, 2026
Management Discussion & Analysis
- Revenue $673.1M, up $665.2M YoY, driven by $653.2M Roche license revenue
- Net income $549.8M vs $86.4M loss YoY, operating margin 83.1% vs negative 1,157.6%
- Roche collaboration best contributor: $653.2M license revenue, versus Pfizer collaboration revenue $9.7M
- Operating cash flow $447.1M vs $181.6M use YoY, cash and securities $1.1B
- Near-term funding sufficient for at least 12 months, with substantial additional capital required long term
Risk Factors
- Newly added commercialization risk: Roche collaboration triggered transition to commercial operations, requiring new sales, compliance and market-access capabilities
- Most materially updated clinical risk: Phase 3 DAYBreak CLL-306 enrolled its first patient in August 2026, expanding exposure to late-stage safety findings
- Regulatory risk: Loper Bright increased litigation and judicial scrutiny of FDA, CMS and HHS interpretations, potentially affecting future pricing and reimbursement
- Competitive risk: Multiple BTK degrader programs now in clinical development, increasing pressure on bexobrutideg’s market opportunity
- Liquidity risk: $1.1 billion in cash, equivalents and marketable securities supports operations through at least the next 12 months, but additional funding remains necessary long term
AI summary of the NRIX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Sanofi discontinued the Phase 1 trial and terminated SAR448272, an oral STAT6 degrader
- Nurix loses eligibility for future development, regulatory and commercial milestones and royalties tied to SAR448272
Item 2.02: Results of Operations and Financial Condition
- Press release announces Nurix Therapeutics’ financial results for the quarter ended August 31, 2026
- Exhibit 99.1 contains the underlying financial results and management commentary for investor review
Item EX-99.1: Item EX-99.1
- Revenue $673.1M, including $653.2M Roche license revenue and $10.0M Sanofi milestone
- Net income $549.8M, or $4.73 diluted EPS, versus $86.4M net loss in the prior-year quarter
Item 2.02: Results of Operations and Financial Condition
- Nurix announced fiscal-quarter results for the period ended May 31, 2026
- Full financial details and management commentary are contained in Exhibit 99.1, the accompanying press release
Item EX-99.1: Item EX-99.1
- Roche collaboration: $700M upfront and up to $2.3B total payments for bexobrutideg, subject to closing conditions
- Development costs shared 40% Nurix and 60% Roche, with equal U.S. profit/loss sharing and tiered ex-U.S. royalties
AI summaries of NRIX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NRIX
Don't miss the next NRIX filing
- Alerts as it files. A push when NRIX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NRIX, by share count.
- Ask anything. An AI agent that reads every NRIX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| van Houte Hans | Sell | Nov 4, 2026 | 3,300 | $15.38 |
| van Houte Hans | Sell | Nov 4, 2026 | 1,469 | $16.20 |
| Ring Christine | Sell | Nov 3, 2026 | 6,113 | $25.83 |
| Ring Christine | Sell | Nov 2, 2026 | 9,527 | $25.74 |
| Hansen Gwenn | M | Nov 2, 2026 | 1,452 | $1.86 |
| Ring Christine | Sell | Nov 2, 2026 | 1,075 | $26.76 |
| Hansen Gwenn | M | Nov 2, 2026 | 1,452 | - |
| Hansen Gwenn | Sell | Nov 2, 2026 | 1,452 | $26.80 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $77.0M | $54.5M | $84.0M |
| Operating Income | - | -$213.0M | -$285.7M |
| Net Income | -$143.9M | -$193.6M | -$264.5M |
| Op. Margin | - | -390.5% | -340.2% |
| Net Margin | -187.0% | -354.9% | -314.9% |
| Balance Sheet | |||
| Total Assets | - | $669.3M | $688.1M |
| Equity | - | $527.0M | $538.7M |
| ROE | - | -36.7% | -49.1% |
| Per Share | |||
| EPS | $-2.65 | $-2.88 | $-3.05 |
| Cash Flow | |||
| Operating CF | - | -$172.6M | -$249.5M |
| CapEx | $8.4M | $9.3M | $14.0M |
Source: XBRL data in Nurix Therapeutics, Inc. (NRIX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate NRIX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 29 | $913.8M |
| Q2 2026 | 28 | $1.08B |
| Q1 2026 | 28 | $662.3M |
| Q4 2025 | 21 | $718.2M |
| Q3 2025 | 24 | $306.3M |
| Q2 2025 | 25 | $414.5M |
| Q1 2025 | 24 | $308.9M |
| Q4 2024 | 20 | $426.5M |
- Morgan Stanley+484.0K (+10%)
- Goldman Sachs Group+468.2K (+58%)
- Bank of America Corp+408.2K (+48%)
- Millennium Management+391.9K (+1874%)
- JPMorgan Chase & Co+321.3K (+660%)
- Citadel Advisors LLC−1.31M (-89%)
- T. Rowe Price Group−865.8K (-16%)
- State Street Corp−248.6K (-5%)
- Vanguard Portfolio Management LLC−221.4K (-15%)
- Dimensional Fund Advisors−116.4K (-8%)
- Ameriprise Financial+24.0K
- Two Sigma Investments+19.1K
- Principal Financial Group+12.9K
- FMR LLC (Fidelity)−5.49M
- Marex Group plc−14.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 199 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NRIX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Oct 15, 2026 | - | - | - |
| 4 | Oct 14, 2026 | - | - | - |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| 10-Q | Oct 13, 2026 | Aug 31, 2026 | Analysis | |
| 4 | Oct 2, 2026 | - | - | - |
| SC 13G | Sep 23, 2026 | - | - | |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| SC 13G | Aug 14, 2026 | - | - | |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 8-K | Jul 9, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
NRIX SEC filings: frequently asked questions
Are NRIX insiders buying or selling?
In the last 90 days, Nurix Therapeutics, Inc. (NRIX) officers, directors and 10% owners reported no open-market purchases and 15 open-market sales worth $1.7 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold NRIX stock?
As of September 30, 2026, the largest Nurix Therapeutics, Inc. (NRIX) holders among the 13F filers tracked by SignalX were BlackRock ($208.7 million), Morgan Stanley ($124.4 million), T. Rowe Price Group ($108.4 million), Vanguard Capital Management LLC ($106.8 million), State Street Corp ($105.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NRIX's revenue in fiscal year 2025?
For the fiscal year ended November 30, 2025 (FY2025), Nurix Therapeutics, Inc. (NRIX) reported revenue of $84.0 million (up 54.0% from FY2024) and a net loss of $264.5 million. Diluted EPS was -$3.05. The figures come from the XBRL data in the 10-K.
What are the main risks in NRIX's latest 10-K?
In the 10-K filed January 28, 2026, Nurix Therapeutics, Inc. (NRIX) flagged: Regulatory risk: FDA partial clinical hold on zelebrudomide enrollment in 2023 due to manufacturing change, lifted in August 2024. Macroeconomic risk: Uncertainty from inflation, interest rates, tariffs, debt ceiling risks, and global conflict impacts clinical trials, supply chain, personnel. (AI summary of the Risk Factors section.)
What did NRIX report in its latest 8-K?
Nurix Therapeutics, Inc. (NRIX) filed an 8-K on November 3, 2026 reporting Item 8.01 (Other Events). Sanofi discontinued the Phase 1 trial and terminated SAR448272, an oral STAT6 degrader.
What are the latest NRIX SEC filings?
Nurix Therapeutics, Inc. (NRIX) filed its latest 10-K annual report on January 28, 2026, a 10-Q quarterly report on October 13, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 4, 2026.
What is NRIX's SEC CIK number?
Nurix Therapeutics, Inc. (NRIX)'s SEC Central Index Key (CIK) is 1549595. EDGAR lists every NRIX filing under that number.
Ask anything about NRIX
The research agent reads NRIX's filings, financials, insider trades and 13F holders, then answers with sources.